Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: Focus on inhaled loxapine as an alternative to injectable agents

Therapeutics and Clinical Risk Management

Volumn 9, Issue 1, 2013, Pages 235-245

  Citrome, Leslie ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Agitation; Antipsychotic; Bipolar disorder; Inhaled loxapine; Mania; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; HALOPERIDOL; LORAZEPAM; LOXAPINE; OLANZAPINE; PLACEBO; ZIPRASIDONE;

AKATHISIA; AREA UNDER THE CURVE; BIPOLAR DISORDER; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTROL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; GLAUCOMA; HUMAN; LUNG DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RESTLESSNESS; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; THROAT IRRITATION; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; URINE RETENTION;

EID: 84881598696     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S31484     Document Type: Review

References (41)

1. Citrome L. Agitation III: pharmacologic treatment of agitation. In: Glick RL, Berlin JS, Fishkind AB, Zeller SL, editors. Emergency Psychiatry: Principles and Practice. Baltimore, MD: Lippincott Williams and Wilkins; 2008:137-148.
2. Citrome L, Volavka J. Violent patients in the emergency setting. Psychiatr Clin North Am. 1999;22(4):789-801.
3. Nolan KA, Shope CB, Citrome L, Volavka J. Staff and patient views of the reasons for aggressive incidents: a prospective, incident-based study. Psychiatr Q. 2009;80(3):167-172.
4. Nolan KA, Volavka J, Czobor P, et al. Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder. J Psychiatr Res. 2005;39(1):109-115.
5. Nolan KA, Czobor P, Roy BB, et al. Characteristics of assaultive behavior among psychiatric inpatients. Psychiatr Serv. 2003;54(7):1012-1016.
6. Volavka J, Citrome L. Pathways to aggression in schizophrenia affect results of treatment. Schizophr Bull. 2011;37(5):921-929.
7. Volavka J, Citrome L. Heterogeneity of violence in schizophrenia and implications for long-term treatment. Int J Clin Pract. 2008;62(8): 1237-1245.
8. Advokat C. A brief overview of iatrogenic akathisia. Clin Schizophr Relat Psychoses. 2010;3(4):226-236.
9. Citrome L, Krakowski M, Greenberg WM, Andrade E, Volavka J. Antiaggressive effect of quetiapine in a patient with schizoaffective disorder. J Clin Psychiatry. 2001;62(11):901.
10. Citrome L, Green L. The dangerous agitated patient. What to do right now. Postgrad Med. 1990;87(2):231-236.
11. Citrome L, Volavka J. Clinical management of persistent aggressive behavior in schizophrenia. Part I: definitions, epidemiology, assessment, and acute treatment. Essent Psychopharmacol. 2002;5(1):1-16.
12. Ahmed U, Jones H, Adams CE. Chlorpromazine for psychosis induced aggression or agitation [review]. Cochrane Database Syst Rev. 2010;4:CD007445.
13. Powney MJ, Adams CE, Jones H. Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) [review]. Cochrane Database Syst Rev. 2012;11:CD009377.
14. Citrome L. Limited evidence on effects of haloperidol alone for rapid tranquillisation in psychosis-induced aggression. Evid Based Ment Health. 2013;16(2):47.
15. Vinogradov S, Fisher M, Warm H, Holland C, Kirshner MA, Pollock BG. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry. 2009;166(9):1055-1062.
16. Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry. 2007;68(12):1876-1885.
17. Wilson MP, Pepper D, Currier GW, Holloman GH Jr, Feifel D. The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry Project Beta Psychopharmacology workgroup. West J Emerg Med. 2012;13(1):26-34.
18. US Food and Drug Administration. NDA Approval Letter, December 21, 2012. Silver Spring, MD: US Food and Drug Administration; 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/022549Orig1s000ltr.pdf. Accessed March 17, 2013.
19. Adasuve® (loxapine) inhalation powder, for oral inhalation use [prescribing information]. Mountain View, CA: Alexza Pharmaceuticals; 2012.
20. Alexza Pharmaceuticals. Alexza receives marketing authorization for Adasuve® (Staccato® loxapine) in the European Union [press release]. Mountain View, CA: Alexza Pharmaceuticals; 2013. Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=196151&p=irolnewsArticle&ID=1787494. Accessed March 17, 2013.
21. Adasuve®: summary of product characteristics [webpage on the Internet]. Mountain View, CA: Alexza Pharmaceuticals; 2012. Available from: http://www.adasuve.com/index-eu.php. Accessed March 17, 2013.
22. Allen MH, Feifel D, Lesem MD, et al. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(10):1313-1321.
23. Lesem MD, Tran-Johnson TK, Riesenberg RA, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry. 2011;198(1):51-58.
24. Kwentus J, Riesenberg RA, Marandi M, et al. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord. 2012;14(1):31-40.
25. Alexza Pharmaceuticals. Adasuve ® (Loxapine) Inhalation Powder NDA 022549: Psychopharmacologic Drug Advisory Committee Briefing Document. Mountain View, CA: Alexza Pharmaceuticals; 2011. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM282900.pdf. Accessed March 19, 2013.
26. US Food and Drug Administration. Adasuve® (Loxapine) Inhalation Powder NDA 022549: Psychopharmacologic Drug Advisory Committee Briefing Document. Silver Spring, MD: US Food and Drug Administration; 2011. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM282897.pdf. Accessed March 19, 2013.
27. European Medicines Agency. Adasuve® Assessment Report. London: European Medicines Agency; 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002400/WC500139407.pdf. Accessed March 17, 2013.
28. Citrome L. Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder. Int J Clin Pract. 2011;65(3):330-340.
29. Citrome L. Inhaled loxapine for agitation revisited: focus on effect sizes from two Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder. Int J Clin Pract. 2012;66(3): 318-325.
30. Noymer P, Myers D, Glazer M, Fishman R., Cassella JV. The Staccato® system: inhaler design characteristics for rapid treatment of CNS disorders. Respiratory Drug Delivery. 2010;1:11-20.
31. Dinh K, Myers DJ, Glazer M, et al. In vitro aerosol characterization of Staccato®loxapine. Int J Pharm. 2011;403(1-2):101-108.
32. Dinh KV, Myers DJ, Noymer PD, Cassella JV. In vitro aerosol deposition in the oropharyngeal region for Staccato® loxapine. J Aerosol Med Pulm Drug Deliv. 2010;23(4):253-260.
33. Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry. 1999;60(Suppl 10): 20-30.
34. Spyker DA, Munzar P, Cassella JV. Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. J Clin Pharmacol. 2010;50(2):169-179.
35. Amoxapine tablet drug label [webpage on the Internet]. Bethesda, MD: National Institute of Health; 2010. Available from: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=19651. Accessed November 12, 2010.
36. Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand. 2008;117(6):412-419.
37. Cassella J, Spyker D, Kwentus J, Lesem M, Fishman R. Rapid improvement in the five-item Positive and Negative Syndrome - Excited Component (PANSS-EC) scale for agitation with inhaled loxapine. 50th Meeting of the NCDEU; June 14-17, 2010; Boca Raton, FL, USA.
38. Citrome L. Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr Drug Saf. 2009;4(3):229-237.
39. US Food and Drug Administration. Adasuve ® (loxapine) Inhalation Powder: Risk Evaluation and Mitigation Strategy. Silver Spring, MD: US Food and Drug Administration; 2012. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM333242.pdf. Accessed March 17, 2013.
40. Citrome L, Nasrallah HA. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opin Pharmacother. 2012;13(11):1599-1613.
41. Citrome L. Evidence-based medicine: it's not just about the evidence. Int J Clin Pract. 2011;65(6):634-635.